Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BGNE BeiGene		$194.32	$146.21 ▼ $248.16	$18.03B	0.57	336,748 shs	331,608 shs
ELAN Elanco Animal Health	$14.75 -0.9%	$13.45	$8.02 ▼ $15.78	$7.33B	1.67	5.05 million shs	1.79 million shs
GLPG Galapagos	$30.24 -0.9%	$28.10	$22.36 ▼ $31.23	$2.00B	0.07	252,771 shs	139,491 shs
MYL Mylan	$15.86	$15.57	$12.75 ▼ $23.11	$8.59B	1.45	6.49 million shs	4,016 shs
OPHLF Ono Pharmaceutical	$11.21 +3.9%	$10.44	$9.20 ▼ $16.05	$5.27B	0.49	7,667 shs	1,124 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BGNE BeiGene	0.00%	0.00%	0.00%	0.00%	+21.38%
ELAN Elanco Animal Health	-0.13%	+2.73%	+7.64%	+80.45%	+7.72%
GLPG Galapagos	+0.69%	+7.09%	+6.08%	+27.76%	+13.00%
MYL Mylan	0.00%	0.00%	0.00%	0.00%	0.00%
OPHLF Ono Pharmaceutical	+3.89%	+20.15%	+4.67%	-5.08%	-19.18%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BGNE BeiGene	1.4909 of 5 stars	3.5	0.0	0.0	0.0	0.6	0.8	0.6
ELAN Elanco Animal Health	1.5015 of 5 stars	1.3	1.0	0.0	0.3	1.9	1.7	1.3
GLPG Galapagos	0.394 of 5 stars	0.8	4.0	0.0	0.0	1.5	0.0	0.6
MYL Mylan	0.7247 of 5 stars	0.0	0.0	0.0	3.5	0.0	1.7	1.3
OPHLF Ono Pharmaceutical	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BGNE BeiGene	3.00	Buy	$274.20	∞ Upside
ELAN Elanco Animal Health	2.50	Moderate Buy	$15.33	3.94% Upside
GLPG Galapagos	1.50	Reduce	$25.33	-16.21% Downside
MYL Mylan	0.00	N/A	N/A	N/A
OPHLF Ono Pharmaceutical	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest MYL, BGNE, ELAN, OPHLF, and GLPG Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/2/2025	ELAN Elanco Animal Health	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$16.00 ➝ $17.00
6/26/2025	ELAN Elanco Animal Health	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform
5/19/2025	ELAN Elanco Animal Health	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$15.00 ➝ $16.00
5/8/2025	ELAN Elanco Animal Health	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$13.00 ➝ $15.00

(Data available from 7/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BGNE BeiGene	$3.32B	0.00	N/A	N/A	$37.10 per share	0.00
ELAN Elanco Animal Health	$4.44B	1.65	$2.23 per share	6.61	$12.33 per share	1.20
GLPG Galapagos	$288.19M	6.91	$0.72 per share	41.73	$47.57 per share	0.64
MYL Mylan	$11.50B	0.75	$8.76 per share	1.81	$23.02 per share	0.69
OPHLF Ono Pharmaceutical	$3.20B	1.65	$1.12 per share	10.01	$11.07 per share	1.01

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BGNE BeiGene	-$881.71M	-$8.24	N/A	N/A	N/A	-25.94%	-25.12%	-14.95%	N/A
ELAN Elanco Animal Health	$338M	$0.74	19.94	16.58	2.91	8.43%	7.54%	3.57%	8/7/2025 (Estimated)
GLPG Galapagos	$80.16M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	7/23/2025 (Estimated)
MYL Mylan	$16.80M	$4.42	29.92	3.52	2.01	2.35%	20.43%	7.72%	N/A
OPHLF Ono Pharmaceutical	$330.31M	$0.70	16.01	∞	N/A	10.24%	6.20%	4.66%	7/28/2025 (Estimated)

Latest MYL, BGNE, ELAN, OPHLF, and GLPG Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	ELAN Elanco Animal Health	$0.1989	N/A	N/A	N/A	$1.19 billion	N/A
7/23/2025	Q2 2025	GLPG Galapagos	-$0.34	N/A	N/A	N/A	$80.13 million	N/A
5/7/2025	Q1 2025	ELAN Elanco Animal Health	$0.31	$0.37	+$0.06	$0.14	$1.17 billion	$1.19 billion
4/23/2025	Q1 2025	GLPG Galapagos	-$0.23	-$2.47	-$2.24	-$2.45	$72.22 million	$97.33 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BGNE BeiGene	N/A	N/A	N/A	N/A	N/A
ELAN Elanco Animal Health	N/A	N/A	N/A	N/A	N/A
GLPG Galapagos	N/A	N/A	N/A	N/A	N/A
MYL Mylan	N/A	N/A	N/A	N/A	N/A
OPHLF Ono Pharmaceutical	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BGNE BeiGene	0.05	1.93	1.72
ELAN Elanco Animal Health	0.68	2.71	1.46
GLPG Galapagos	N/A	7.95	7.86
MYL Mylan	0.84	0.93	0.53
OPHLF Ono Pharmaceutical	0.13	3.07	2.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BGNE BeiGene	48.55%
ELAN Elanco Animal Health	97.48%
GLPG Galapagos	32.46%
MYL Mylan	88.18%
OPHLF Ono Pharmaceutical	N/A

Insider Ownership

Company	Insider Ownership
BGNE BeiGene	7.43%
ELAN Elanco Animal Health	0.89%
GLPG Galapagos	2.91%
MYL Mylan	0.59%
OPHLF Ono Pharmaceutical	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BGNE BeiGene	9,000	97.62 million	90.20 million	Optionable
ELAN Elanco Animal Health	9,000	496.65 million	492.23 million	Optionable
GLPG Galapagos	1,310	65.90 million	N/A	Optionable
MYL Mylan	35,000	541.55 million	N/A	Optionable
OPHLF Ono Pharmaceutical	3,853	469.71 million	N/A	Not Optionable

MYL, BGNE, ELAN, OPHLF, and GLPG Headlines

Recent News About These Companies

Ono Pharmaceutical (OTCMKTS:OPHLF) Trading 13.1% Higher - Here's What Happened

July 14 at 3:07 PM | marketbeat.com

Ono Pharmaceutical (OTCMKTS:OPHLF) Stock Passes Above 50-Day Moving Average - Here's What Happened

July 11, 2025 | marketbeat.com

Ono Pharmaceutical (OTCMKTS:OPHLF) Shares Gap Up - Time to Buy?

July 10, 2025 | marketbeat.com

Ono Pharmaceutical (OTCMKTS:OPHLF) Shares Gap Down - Here's Why

June 25, 2025 | marketbeat.com

Pharma company announces it will lay off 83 Boston-area employees

April 30, 2025 | msn.com

Pharmaceutical company to cut 83 Boston-area jobs in downsize

April 28, 2025 | masslive.comM

Ono Pharmaceutical Taps Jorna Therapeutics for RNA-Editing Drug Discovery Partnership

April 21, 2025 | precisionmedicineonline.comP

Ono Pharmaceutical Enhances Governance and Diversity Initiatives

March 24, 2025 | tipranks.com

Ono scoops Ionis' hematology candidate sapablursen for up to $940M

March 13, 2025 | bioworld.comB

Ono earmarks $940m to gain rare blood cancer therapy from Ionis

March 12, 2025 | msn.com

ONO-4915 by Ono Pharmaceutical for Autoimmune Disorders: Likelihood of Approval

January 5, 2025 | pharmaceutical-technology.comP

ONO-4685 by Ono Pharmaceutical for T-Cell Lymphomas: Likelihood of Approval

December 30, 2024 | pharmaceutical-technology.comP

Risk adjusted net present value: What is the current valuation of Ono Pharmaceutical’s Vimseltinib?

December 16, 2024 | pharmaceutical-technology.comP

Ono Enters into Drug Discovery Collaboration Agreement with Congruence Therapeutics to Generate Novel Small Molecule Correctors in the Oncology Area

December 5, 2024 | tmcnet.com

Equillium keeps equilibrium in GVHD after Ono no-go

November 1, 2024 | bioworld.comB

Sanofi enters talks with private equity firm to sell controlling stake in consumer health unit Opella

October 11, 2024 | fiercepharma.comF

Ono, Boehringer add to cancer pipelines with licensing deals

October 10, 2024 | pharmaphorum.comP

Kinaxis to Bolster Supply Chain Operations of Ono Pharmaceutical

October 7, 2024 | standard-journal.comS

Life-saving cancer drug a boon to patients in Japan, but price prompts debate

October 4, 2024 | mainichi.jpM

Nectar Classic Hybrid Mattress review 2024

September 24, 2024 | fortune.com

The best Plank mattresses of 2024, tested and reviewed

September 24, 2024 | fortune.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
Top Steel Picks for the Coming Infrastructure Boom
By Chris Markoch | June 25, 2025
View Top Steel Picks for the Coming Infrastructure Boom
3 Top Stocks Under $20 Riding the “Made in America” Wave
By Chris Markoch | July 3, 2025
View 3 Top Stocks Under $20 Riding the “Made in America” Wave

MYL, BGNE, ELAN, OPHLF, and GLPG Company Descriptions

BeiGene NASDAQ:BGNE

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC. The company is also developing inhibitors comprising Sonrotoclax (BGB-11417), BGB-10188, BGB-21447, Ociperlimab (BGB-A1217), Surzebiclimab (BGB-A425), BGB-15025, BGB-26808, Lifirafenib (BGB-283), BGB-3245, BGB-30813, and BGB-43395; antibodies, including Zanidatamab, BGB-A445, and BGB-A3055, as well as BGB-16673, a BTK-targeted CDAC, and BGB-24714, a SMAC mimetic. It has collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, Bristol Myers Squibb company, Shandong Luye Pharmaceutical Co., Ltd., Nanjing Leads Biolabs, Inc., EUSA Pharma, Assembly Biosciences, Inc., Bio-Thera Solutions, Ltd., and Nanjing Leads Biolabs Co., Ltd. The company was incorporated in 2010 and is based in Grand Cayman, the Cayman Islands.

Elanco Animal Health NYSE:ELAN

$14.75 -0.14 (-0.93%)

As of 02:46 PM Eastern

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Galapagos NASDAQ:GLPG

$30.24 -0.28 (-0.90%)

As of 02:45 PM Eastern

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Mylan NASDAQ:MYL

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary diseases. In addition, it markets OTC products, including Cold-EEZE, MidNite, Vivarin, Brufen, CB12, and EndWarts. The company offers its products to therapeutic areas, such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women's health. Its customers include retail pharmacies, wholesalers and distributors, payers, and insurers and governments, as well as institutions, such as hospitals. Mylan N.V. has collaboration and license agreements with Pfizer Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; Fujifilm Kyowa Kirin Biologics Co. Ltd; and Revance Therapeutics, Inc. The company was founded in 1961 and is based in Hatfield, the United Kingdom.

Ono Pharmaceutical OTCMKTS:OPHLF

$11.21 +0.42 (+3.89%)

As of 07/14/2025 03:43 PM Eastern

Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes; Onoact Intravenous Infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease; Ongentys tablets for Parkinson's disease; Parsabiv, an intravenous infusion for dialysis patients; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has a collaboration with Adimab, LLC to discover novel antibody drugs; a research collaboration with Turbine Ltd. to identify and validate novel oncology targets; Harvard University for validating novel therapeutic targets; and a strategic drug discovery collaboration with Sibylla Biotech in central nervous system disorders. The company was founded in 1717 and is headquartered in Osaka, Japan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time